Antibodies Binding to ILT4

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human IL...

Full description

Saved in:
Bibliographic Details
Main Authors Schebye, Xiao Min, Bee, Christine, Chen, Diana Yuhui, Toth, Joseph, Selby, Mark J, Korman, Alan J, Chen, Guodong, Lonberg, Nils, Deyanova, Ekaterina G, Han, Michelle Minhua, Huang, Richard Y, Liang, Linda, Rankin, Andrew, Deng, Xiaodi, Truong, Hong-An
Format Patent
LanguageEnglish
Published 12.03.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
Bibliography:Application Number: US201916506754